anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

239,401-239,460 of 319,975

filter-aware
07
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Setup1 hit
08
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Setup1 hit
09
Includes a disclaimer at the bottom regarding FDA status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Setup1 hit
10
Includes a standard Theranos FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Setup1 hit
11
The slide showcases hardware components for clinical chemistry, immunochemistry, hematology/immunology, and molecular biology.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
12
The slide displays six distinct hardware components: Camera, Material Handling Robot, Cartridge, Sonicator, Thermocycler, and Centrifuge.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
13
The slide includes a disclaimer about FDA clearance status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
14
The slide includes a disclaimer about FDA approval status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
15
Includes a disclaimer regarding FDA clearance status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
16
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
17
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
18
The slide includes a standard FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
19
The slide includes a disclaimer about FDA status at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
20
Includes a regulatory disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
21
The slide displays a central cartridge/tray surrounded by individual components with labels and volume specifications.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
22
The slide includes a disclaimer at the bottom regarding FDA approval status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
23
The slide is essentially a product reveal combined with a legal disclaimer.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
24
The image shows the internal components of a Theranos blood-testing device.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
25
The image shows the internal mechanics of a diagnostic or sequencing instrument.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
26
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
27
The slide is a frame from a video presentation showing the internal mechanics of a blood testing device.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
28
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
29
The slide is a frame from a video demonstration of the Theranos Edison device.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
30
This is a system screenshot, not a presentation slide.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
31
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
32
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
33
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
34
The study design follows the CLSI EP05-A3 standard.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
35
References CLSI EP05-A3, a standard for evaluation of precision of quantitative measurement procedures.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
36
The slide includes a disclaimer at the bottom regarding FDA clearance status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
37
The slide references CLSI EP09-A3, a standard for method comparison and bias estimation using patient samples.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
38
The slide includes a disclaimer regarding FDA clearance status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
39
Includes regression equations, r-squared values, sample sizes, median bias, and Allowable Total Error (ATE) metrics for each lipid type.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
40
The slide includes a disclaimer at the bottom regarding FDA clearance.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
41
The slide uses a table to validate performance against industry-standard benchmarks.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Evidence1 hit
42
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
43
Slide 32 from a Theranos presentation deck.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
44
References CLSI EP05-A3 standard.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
45
The slide includes a disclaimer about FDA clearance status and definitions for (L) and (H) samples.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
46
The slide outlines the clinical study parameters for a Herpes diagnostic test.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
47
Includes FDA clearance references and disclaimer.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
48
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
49
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
50
The slide outlines a four-step laboratory workflow involving staining, lysis/fixation, loading, and algorithmic analysis.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
51
This slide is from the Theranos deck, illustrating their proprietary image processing pipeline.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Complication1 hit
52
References CLSI EP05-A3 standard for precision performance testing.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
53
Includes FDA disclaimer and definitions for (L) and (N) cell counts.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
54
The slide uses a standard table format to define the parameters of a clinical validation study.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
55
The slide presents method comparison data (regression analysis) for three different cell types, including statistical metrics like r-squared, median bias, and Allowable Total Error (ATE).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
56
The slide shows three scatter plots with regression lines, R-squared values, and performance metrics (bias, ATE, TE).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
57
Includes technical definitions of error metrics and regulatory disclaimers.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
58
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
59
Includes FDA disclaimer at the bottom.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
60
Theranos | Investor Conference Presentation Deck | 88 slidesTheranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
61
The slide compares the assay's LoD (480 copies/mL) against the CDC Zika test LoD (930 copies/mL).Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
62
n = 3 replicates per test; FDA disclaimer present.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
63
The slide includes a disclaimer that the technology is not FDA cleared.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
64
n = 3 replicates per test; FDA disclaimer present.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
65
The slide includes a disclaimer at the bottom regarding FDA clearance status.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit
66
The slide presents experimental validation data for a diagnostic assay.Theranos | Investor Conference Presentation Deck | 88 slides · Theranos
Conference presentation Investor relations Beat · Solution1 hit